Company ProfilePremium

Afya Limited

Company Profile Analysis

Ticker: AFYA

ESOMAR 23 Corporate BadgeISO Certifications Badge
Afya Limited - Company showcase

Year Founded & Workforce

1999

9,395 Employees

Afya Limited logo

Afya Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Afya Limited Overview

AttributeDetail
Legal nameAfya Limited
Former / predecessor namesAfya Educacional (IPO-era brand). Operating predecessors were NRE Educacional and Medcel.
Origin of operations1999: first medical school (ITPAC, Tocantins)
Incorporation22 March 2019, Cayman Islands (exempted company)
Registered officeUgland House, P.O. Box 309, George Town, Grand Cayman KY1-1104 (per the 2026 merger agreement)
Operating headquartersBelo Horizonte, Minas Gerais, Brazil. Press-release datelines moved from Nova Lima, MG to Belo Horizonte during 2025.
Brazilian tax ID (CNPJ)33.858.154/0001-78
ListingsNasdaq Global Select: AFYA (Class A common shares). B3: A2FY34 (BDRs).
ISINKYG011251066
CUSIP—
Fiscal year end31 December
Employees9,680 (FY2023); 9,717 (FY2024); 9,395 (FY2025). Source: FY2025 6-K ESG table.
Auditorconfirm against the FY2025 Form 20-F
Share countAbout 88.5M shares outstanding (aggregator data, 2026)
Market capitalisationAbout US$1.23bn (88.5M shares × US$13.92 close on 6 Oct 2026). Aggregator range in 2026: US$1.23–1.36bn.
Credit ratingMoody's local-scale AAA.br, stable outlook, reaffirmed 5 May 2026
Websitewww.afya.com.br; investor relations at ir.afya.com.br
Controlling shareholdersBertelsmann SE & Co. KGaA (through Erste WV Gütersloh GmbH) and the Esteves family, which together form the controlling bloc

The listed company is Afya Limited, a Cayman Islands exempted company. Its Class A common shares trade on Nasdaq under the ticker AFYA, and its Brazilian Depositary Receipts trade on B3 as A2FY34.

The ISIN supplied in the request (KYG011251066) belongs to this issuer. The listing has not moved and the entity has not been renamed.

On 23 September 2026 Afya signed a binding agreement to merge into YDUQS Participações S.A. (B3: YDUQ3). On completion:

  • Afya would cease to exist as a separate legal entity.

  • Afya would be delisted from Nasdaq.

  • Afya shareholders would receive newly issued YDUQS shares and hold 69% of the combined company.

The transaction is pending. It still needs approval from CADE (Brazil's antitrust authority) and from both companies' shareholders.

Afya is Brazil's largest private medical-education group by number of authorised medical-school seats. It had 3,768 operating seats at mid-2026, roughly 10–11% of private seats nationally.

Around that licence-protected undergraduate core it has built a "physician-centric ecosystem". This ecosystem follows a doctor from medical school through:

  • residency preparation;

  • specialist and graduate programmes;

  • digital clinical-decision tools (Afya Whitebook);

  • practice-management software (Afya iClinic).

Brazil's federal government tightly rations medical seats through its Ministry of Education, MEC, and the Mais Médicos programme. That scarcity gives the core business strong pricing power:

  • The medical-school net ticket was about R$9,443 per student per month in 1H26.

  • The business has very high occupancy.

  • Adjusted EBITDA margins have run in the low-to-mid 40s.

In FY2025 Afya generated R$3.70bn of revenue and R$1.68bn of adjusted EBITDA, and has met or exceeded guidance every year since 2H19. Its strategic identity is now in transition. The pending all-share merger into YDUQS would fold Afya into a diversified Brazilian higher-education group in which medicine represents about 45% of revenue. Bertelsmann would remain the anchor shareholder, and Afya's CEO would lead the combined company.


Company self-description (paraphrased from the 2026 6-K boilerplate)

Afya describes itself as Brazil's leading medical education group by number of medical-school seats. It frames itself as an end-to-end ecosystem that serves physicians across their whole career:

  • as medical students;

  • through residency preparation and graduate programmes;

  • through continuing medical education;

  • through medical-practice solutions that help doctors run their practices.

Reporting segments (latest definitions, 2Q26 6-K)

  1. Undergraduate. Formerly called "Undergrad". It covers undergraduate degrees in medicine, other health sciences and non-health programmes.

  2. Continuing Education. This covers residency-preparation programmes, specialisation-exam preparation, other medical capability courses, and specialisation and graduate courses in medicine. Delivery is digital and in-person.

  3. Medical Practice Solutions (MPS). This covers clinical-decision tools, clinical (practice) management and doctor–patient relationship tools. It also provides access, demand-generation and efficiency services to healthcare players such as pharmaceutical companies.

Revenue model

Revenue typeFY2025 (BRL Mn)Share of gross segment revenueCharacter
Undergraduate tuition3,255.487.7%Monthly tuition fees, recognised over the semester. Driven by occupancy, seat maturation and ticket.
Continuing Education284.57.7%Mostly monthly tuition from business-to-physician (B2P) customers. The residency-journey product includes e-books recognised at a point in time, which concentrates revenue in Q1 and Q4. Business-to-business (B2B) revenue was R$26.8M.
Medical Practice Solutions171.34.6%Subscription/SaaS from physicians (Whitebook, iClinic, Shosp), R$152.6M, plus B2B pharma and healthcare solutions, R$18.7M
Inter-segment eliminations-14.0——

Revenue is overwhelmingly recurring tuition.

Source: FY2025 6-K. Shares are computed on gross segment revenue before eliminations.

By model type, about 95% of revenue is service or tuition revenue that behaves like a subscription. About 4% is SaaS or app subscription. B2B and advertising-style revenue is about 1%. Product sales are immaterial apart from e-books inside Continuing Education.

Value-chain position and customers

Afya sits at the start of the physician supply chain, where it has unusual pricing power.

Undergraduate customers: are students and their families. Fees are financed:

  • privately, in most cases;

  • through FIES (federal student financing);

  • through ProUni (tax-incentive scholarships). In FY2025, 16,148 students were on FIES or ProUni, equal to 18.8% of undergraduates (FY2025 6-K ESG table).

Continuing Education and MPS customers: are practising physicians (B2P) and pharmaceutical companies, hospitals, labs and other healthcare players (B2B).

End-markets: - Brazilian private higher education in medicine and health;

  • post-graduate medical education;

  • Brazilian health-IT for physicians (clinical decision support, EMR and practice management).

Independent characterisation

Economically, Afya is a regulated-scarcity asset with a digital option attached.

The undergraduate medical business generates almost all profit and cash:

  • 1H26 medical-school revenue of R$1,499.4M was 76% of the R$1,984.8M group total.

  • Seat licences are hard to obtain.

  • Demand for medical places far exceeds supply.

  • Tuition is high and inflation-linked.

The "ecosystem" segments have grown more slowly than management once projected:

  • MPS revenue grew 5.9% in FY2025.

  • Total MPS monthly active users fell 7.7% in FY2025 and a further 7.9% year on year in 1H26.

In 2026 management launched an "investment cycle" to deepen physician engagement, which is compressing margins. Separately, the ENAMED national medical-graduate exam has introduced quality-linked seat sanctions. The underlying thesis has therefore shifted from "scarcity forever" to "scarcity, subject to quality compliance."

Strategy

Stated strategy, paraphrased from the FY2025 and 2Q26 6-Ks

Brand ambition: Management describes 2026 as a "new phase" in which Afya aims to be the go-to brand for every Brazilian physician at every career stage.

2026 investment cycle: The plan is to widen Afya's audience, strengthen its digital products and deepen engagement. The goal is to grow the physician base and keep undergraduate student acquisition costs structurally low. Management also sees this as building a platform for future B2B revenue.

Undergraduate: The focus is on maturing seats, applying ticket discipline and running a unified national intake for medicine. Health sciences are growing as a diversification lever: students rose 18% in 1H26.

Capital allocation: M&A is pursued only when returns clear internal thresholds. Excess capital is returned through dividends (40% of FY2025 net income) and buybacks.

Return framing: Management argues that an 11% LTM FCFE yield plus 13% EPS growth implies about 24% potential annual equity return at a constant multiple.

Strategic initiatives, last 24 months

InitiativeDateDescription / targetsStatus
Merger with YDUQSTalks confirmed about 24 Aug 2026; signed 23 Sep 2026All-share merger with a 69/31 split. Synergy NPV of R$2.0–2.2bn, about 80% captured within three years. Pro-forma leverage falls from 1.6x to 1.2x. Expected close within about 12 months; long-stop date 31 Mar 2028.Pending: CADE review and shareholder votes
2026 ecosystem investment cycleAnnounced Mar 2026Higher payroll, sales and marketing spending in Continuing Education and MPS. Capex guidance rises to R$340–380M, from R$304M ex-licences in FY2025.In execution; margin dilutive
Liability managementOct–Nov 2025R$1.5bn notes issued; SoftBank facility and preferred shares retired; duration extended to 3.6–3.7 yearsCompleted
Shareholder remunerationMar 2025 onwardFirst dividend (20% of FY2024 net income); FY2025 dividend raised to 40%; 4.0M-share buyback through Dec 2026, of which about 60% remained in March 2026 and 2.7M shares were repurchased in 1H26Ongoing
Unified medical-school intake2025–26A single admissions process across all medical schoolsOperating
Seat expansion via MEC authorisations2025–26Bragança +100, Pato Branco +2, Abaetetuba +63 (with Cametá relinquished)Completed
ENAMED response2,026Afya filed appeals with INEP over its 2025 results. The next ENAMED edition was expected in October 2026.Ongoing
ESG programmeOngoingQuarterly ESG KPIs; own solar generation; free consultationsOngoing

Medium-term financial targets

Management issues only one-year guidance. For FY2026 that is revenue of R$3,950–4,100M, adjusted EBITDA of R$1,700–1,800M and capex of R$340–380M. Medium-term targets are not publicly disclosed. The merger documentation implicitly replaces any standalone long-term plan with combined-company synergy targets.

Products & Services

Undergraduate segment

OfferingDescriptionTarget customerScale / metricPricing model
Afya medical schools (MD degree, six years)On-campus undergraduate medicine across the network. Legacy brands include ITPAC, UNIPTAN, UniRedentor, Unigranrio, FESAR, FCMPB, Santo Agostinho, UNIFIPMoc, FIP Guanambi, Garanhuns, UNIDOM and FUNIC; units are increasingly branded "Afya".Secondary-school graduates and career changers3,768 operating seats (2026); 26,421 students (1H26)Monthly tuition. Net average ticket was R$9,443/month in 1H26, up 3.9%.
Unified intake processA single national admission process across all Afya medical schools, launched before 2026. Described by management as a key enabler of candidate quality and efficiency.Medical applicantsNot quantified—
Undergraduate health sciencesDentistry, nursing, radiology, psychology, pharmacy, physical education, physiotherapy, nutrition, biomedicineHealth-career students30,350 students (1H26), up 18%Monthly tuition (ticket not disclosed)
Other non-health undergraduateBusiness administration, accounting, law, civil and industrial engineering, and othersGeneral higher-education students37,367 students (1H26)Monthly tuition
Free clinical services (social mission)Free clinical consultations delivered by students and clinicsLocal communities897,793 consultations (FY2025)Free

Continuing Education segment

OfferingDescriptionTarget customerMetricPricing
Afya Residency Journey (heritage brand Medcel)Residency-exam preparation, mostly online, including e-books and question banksFinal-year students and graduates9,244 students (1H26); 12,990 at FY2025 end, down 20.7% YoYCourse fees plus e-books recognised at a point in time
Afya Graduate Journey (heritage brand IPEMED)Medical specialisation and graduate programmes, delivered in-person and hybridPractising physicians10,213 students (1H26), up 12.8%Monthly tuition
Other courses (B2P)Short-term programmes and capability courses. Includes content from the Além da Medicina, Cardiopapers and Medical Harbour acquisitions (integration status not fully disclosed).PhysiciansPart of 36,780 "other" studentsLower ticket per student
Continuing Education B2BTraining programmes for institutionsHospitals, healthcare companiesB2B revenue R$26.8M (FY2025); R$9.1M in 1H26, down 25.4%Contracts

Medical Practice Solutions segment

OfferingDescriptionTarget customerMetricPricing
Afya Whitebook (from PEBMED, acquired 2020)Mobile and web clinical-decision app with drug references, protocols and calculatorsPhysicians and medical students150,048 Clinical Decision active payers (1H26), down 5.9%Subscription
Afya iClinic (acquired 2021)Cloud practice-management software and electronic medical records, with telemedicine and digital-prescription featuresPhysicians in private practicePart of 50,499 Clinical Management payers, up 20.4%SaaS subscription
Shosp (acquired 2021)Clinic-management softwareMulti-physician clinicsIncluded in Clinical ManagementSaaS (reclassified to B2P in FY2025)
Glic (via Quasar, acquired 2022)Diabetes-management app linking physician and patientPhysicians and patients——
Medicinae (acquired 2021)Financial and receivables services for physiciansPhysicians——
Cliquefarma (acquired 2021)Drug-price comparison platformPatients, pharmacies——
RX PRO (acquired 2021)Pharma demand-generation and medical-representative solutions (B2B)Pharmaceutical companiesMPS B2B revenue R$18.7M (FY2025), down 16.1%B2B contracts
Afya Papers / Cardiopapers / Medical Harbour content (acquired 2021–22)Specialty content platformsSpecialists—Subscription

Ecosystem metric

Metric2Q253Q254Q251Q262Q26
Ecosystem outreach (users)301,706303,964300,646303,553294,816
MPS monthly active users230,468227,941220,051220,528212,158

Source: 2Q26 6-K Table 5. Launch years for products follow their acquisition dates, and Afya does not disclose version histories. Product-level pricing is not publicly disclosed except for the medical-school net ticket.

Financial Narrative

All figures are R$M unless noted. FY2021–22 come from the 4Q22 6-K, FY2023–25 from the FY2025 6-K, which shows audited FY2023–24 and unaudited FY2025. LTM 2Q26 figures are computed from the 2Q26 6-K.

Income statement

Notes on the income statement:

  • The FY2024 dividend was 20% of net income, about R$130M (computed).

  • The FY2025 dividend is R$3.446838 per share (R$307.4M), declared on 12 March 2026.

  • FY2021–22 adjusted EBITDA margins are calculated on adjusted net revenue, which excludes COVID-era mandatory tuition discounts.

Margins and growth (computed)

The revenue CAGR from FY2021 to FY2025 on reported revenue is 21.1% (computed). Organic growth ex-acquisitions was 9.2% in FY2025 and 12.7% in FY2024.

LTM and 2026 run-rate

FY2026 guidance excludes acquisitions completed after the guidance was issued:

  • Revenue: R$3,950–4,100M.

  • Adjusted EBITDA: R$1,700–1,800M.

  • Capex: R$340–380M.

The company reaffirmed this guidance on 13 August 2026.

Balance sheet

Notes:

  • FY2021 cash is derived from the FY2022 cash balance and its disclosed 46.0% YoY increase.

  • FY2022 gross debt and seller payables come from the 4Q22 cost-of-debt table.

  • At 30 June 2026: cash R$1,006.5M; loans R$2,047.9M (R$126.4M current, R$1,921.5M non-current); seller payables R$352.5M; net debt ex-IFRS 16 R$1,394.0M; lease liabilities R$1,070.3M; total assets R$9,326.6M; equity R$4,928.8M; treasury shares R$410.4M.

Cash flow

Notes:

  • The company reported its own FY2025 "Free Cash Flow" of R$1,056M using a different definition.

  • Reported capex including licences was R$404.0M in FY2025 and R$392.6M in FY2024.

  • In 1H26: OCF R$797.8M; dividends paid R$314.9M; buybacks R$133.0M (2.7M shares); company-defined free cash flow to equity R$423.4M. Payout was 105.8% of FCFE.

Ratios (computed from reported figures)

A traditional cash conversion cycle is not meaningful for Afya because it carries no material inventory. Receivable days are shown instead. Current trade receivables rose to R$819.7M at 2Q26 from R$717.4M at year-end 2025, which is partly seasonal.

Commentary on trends, inflections and drivers

Growth phases

2019–2023: acquisition-led hypergrowth: Reported revenue rose from R$1.72bn in FY2021 to R$2.88bn in FY2023. Revenue grew 35.5% in FY2022, but only about 18.5% of that was organic. Key acquisitions were Unigranrio in 2021, FIPMoc and Guanambi in 2021, DelRey in January 2023, and a string of digital deals.

Adjusted EBITDA margins fell from 43.1% in FY2021 to 40.6% in FY2023, for three reasons:

  • integration drag;

  • start-up losses on the new Mais Médicos campuses;

  • Medcel weakness in a more competitive residency-prep market (4Q22 6-K).

FY2024–25: margin inflection and harvest: Margins expanded 360 bps in FY2024 to 44.1% and a further 130 bps in FY2025 to 45.4%. Management cites:

  • higher undergraduate and Continuing Education gross margins;

  • restructuring within Continuing Education and MPS;

  • SG&A efficiency (FY2025 6-K).

Operating margin rose from 26.7% to 32.8% over FY2023–25. Net income grew 60.1% in FY2024 and 18.4% in FY2025, helped by lower amortisation of acquired intangibles and a low effective tax rate.

2026: deliberate re-investment: Guidance implies the adjusted EBITDA margin will fall to about 43.5% at the midpoint. Year to date, the 1H26 margin of 46.2% was 190 bps lower year on year, and the 2Q26 margin of 41.8% was 180 bps lower.

Revenue growth has also slowed:

  • 1H26: +7.0%.

  • 2Q26: +5.7%.

The organic drivers have narrowed to medical-ticket increases (+3.9%) and seat maturation, with medical student growth of only +2.7% year on year.

Taxation

FY2025 tax expense rose to R$92.5M from R$27.5M. The effective rate was 10.7%, versus 4.1%. The rise reflects an additional CSLL (social contribution) provision under Brazil's implementation of the OECD Pillar Two global minimum tax, partly offset by recognition of deferred tax assets.

In 2Q26 the effective tax rate fell to about 1%. Management cites a "tax impact" from Pillar Two implementation, and a non-current income-tax payable of R$50.0M appeared on the balance sheet.

Tax volatility is therefore a live issue for EPS forecasting. It is also central to the YDUQS deal, because analysts flagged higher income-tax exposure at YDUQS.

Deleveraging and liability management

Net debt ex-IFRS 16 fell from R$1,814.9M to R$1,369.5M during FY2025, despite the FUNIC acquisition, dividends and buybacks. Leverage fell from 1.2x to 0.8x.

The October 2025 R$1.5bn notes refinanced the cheap SoftBank facility:

  • The SoftBank facility cost 5.6% per year, or 40% of CDI.

  • The new notes pay CDI + 0.70% (R$500M, due October 2028) and CDI + 0.85% (R$1,000M, due October 2030).

  • Average duration lengthened from 2.4 to 3.6 years. At 2Q26 it was 3.7 years.

The trade-off is cost. Average cost of debt rose to 15.1% per year in 1H26, from 12.7% in 1H25, because the subsidised SoftBank tranche was replaced at market rates. This is why the net finance result has not fallen even as net debt declined.

Cash generation

Operating cash conversion stayed above 90% throughout, apart from 87.8% in 1H26. Simple free cash flow (OCF minus capex) rose from about R$0.8bn in FY2023 to about R$1.17bn in FY2025. Capital allocation has pivoted from M&A to shareholder returns: R$447.9M was returned in 1H26 alone.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Revenue by Segment

Segment (BRL Mn)FY2024FY2025

Undergraduate revenue

2,895.73,255.4

Continuing Education revenue

255.4284.5

Medical Practice Solutions revenue

161.8171.3

Inter-segment eliminations

-8.6-14.0

Total revenue

3,304.33,697.3

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Segment growth and mix (%)

Segment growth and mix (%)FY2024FY2025

Undergraduate YoY growth (%)

—12.4

Continuing Education YoY growth (%)

—11.4

Medical Practice Solutions YoY growth (%)

—5.9

Undergraduate % of gross segment revenue

87.487.7

Continuing Education % of gross segment revenue

7.77.7

Medical Practice Solutions % of gross segment revenue

4.94.6

Revenue by Segment and Revenue by Segment (BRL)

Undergraduate sub-line (BRL Mn)FY2024FY2025

Medical school revenue

2,477.92,789.2

Health science revenue

236.8261.7

Other non-health undergraduate revenue

181.0204.5

Medical school net avg ticket ex-acquisitions (R$ per month)

8,8099,060

Operating medical seats

3,5433,705

Medical students, end of period

24,25525,556

Revenue by Segment (1H2025–1H2026)

Segment (BRL Mn)1H20251H2026

Undergraduate

1,641.51,762.2

of which Medical school

1,407.31,499.4

of which Health science

130.6147.5

of which Other undergraduate

103.5115.3

Continuing Education

137.5143.9

Medical Practice Solutions

84.085.3

Total revenue

1,855.81,984.8

Revenue by Segment (FY2021–FY2022)

Legacy segment (BRL Mn)FY2021FY2022

Undergrad (reported)

1,498.42,037.9

Continuing Education (legacy)

73.0108.8

Digital Services (legacy)

152.0190.0

Inter-segment

-4.0-7.6

Total reported net revenue

1,719.42,329.1

Income Statement and Per-Share Data

Metric (BRL Mn)FY2021FY2022FY2023FY2024FY2025

Revenue (reported)

1,719.42,329.12,875.93,304.33,697.3

Adjusted net revenue (FY21–23 non-GAAP)

1,752.72,319.12,874.13,304.33,697.3

Cost of services

——1,109.81,215.61,313.9

Gross profit

——1,766.12,088.72,383.4

SG&A

——940.11,008.41,113.1

Operating income (EBIT)

——767.11,012.11,213.1

Adjusted EBITDA

754.8961.91,165.71,455.61,680.3

Net finance result

——-347.0-347.5-366.1

Pre-tax income

——429.6676.4860.9

Income tax expense

——24.227.592.5

Net income

242.3392.8405.4648.9768.4

Net income attributable to owners

——386.3631.5752.5

Adjusted net income

440.4535.1591.1820.3901.7

Basic EPS (BRL)

2.394.144.307.018.32

Diluted EPS (BRL)

——4.276.938.24

Dividends per share declared for the fiscal year (BRL)

000—3.45

Margin Analysis (%)

Ratio (%)FY2021FY2022FY2023FY2024FY2025

Revenue growth YoY

—35.523.514.911.9

Gross margin

——61.463.264.5

Operating margin

——26.730.632.8

Adjusted EBITDA margin (company basis)

43.141.540.644.145.4

Net margin

14.116.914.119.620.8

Effective tax rate

——5.64.110.7

Income Statement and Margin Analysis (%)

Metric (BRL Mn)1H20251H2026LTM 2Q26FY2026 guidance midpoint

Revenue

1,855.81,984.83,826.34,025.0

Adjusted EBITDA

892.8918.01,705.51,750.0

Adjusted EBITDA margin (%)

48.146.244.643.5

Net income

433.6463.1797.9—

Basic EPS (BRL)

4.695.108.73—

Capex

225.1120.0—360.0

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Balance Sheet

Metric (BRL Mn)FY2021FY2022FY2023FY2024FY2025

Total assets

———8,829.59,357.9

Cash and equivalents

748.71,093.1553.0911.01,125.4

Loans and financing, current

———363.660.7

Loans and financing, non-current

———1,831.61,993.6

Accounts payable to selling shareholders

—528.7—530.8440.6

Gross debt incl. seller payables (ex-leases)

—2,473.8—2,725.92,494.9

Lease liabilities (IFRS 16)

———978.31,065.7

Net debt ex-IFRS 16

1,378.91,380.7—1,814.91,369.5

Net debt incl. IFRS 16

———2,793.32,435.2

Intangible assets incl. goodwill

———5,532.85,588.0

Total equity

———4,310.64,891.2

Working capital (current assets minus current liabilities)

———449.61,058.1

Cash Flow and Margin Analysis (%)

Metric (BRL Mn)FY2021FY2022FY2023FY2024FY2025

Operating cash flow before income tax paid

666.6877.01,088.81,453.21,547.6

Net cash from operating activities

630.9843.91,043.61,432.71,531.6

Capex, cash (PP&E plus intangibles)

—297.0245.4392.6364.0

Free cash flow (OCF minus capex, computed)

—546.9798.21,040.11,167.6

Acquisitions of subsidiaries, net of cash

—99.4815.0627.6144.1

Dividends paid

——18.818.3146.8

Share buybacks

—152.312.40.077.0

Operating cash conversion ratio (%)

100.894.4—102.293.7

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2021FY2022FY2023FY2024FY2025

ROE, net income / year-end equity (%)

———15.115.7

ROE, net income / average equity (%)

————16.7

ROA, net income / average assets (%)

————8.4

ROIC, NOPAT / (equity + net debt ex-IFRS 16) (%)

———15.817.3

Current ratio (x)

———1.392.20

Gross debt / equity, ex-leases (x)

———0.630.51

Net debt ex-IFRS 16 / adjusted EBITDA (x)

1.81.4—1.20.8

Net debt incl. IFRS 16 / adjusted EBITDA (x)

———1.91.4

EBIT / finance expenses (x)

——1.682.212.16

Adjusted EBITDA / finance expenses (x)

——2.553.173.00

Asset turnover, revenue / average assets (x)

————0.41

Receivable days, current trade receivables / revenue × 365

———65.870.8

Revenue by Region and Region Margins & Growth (%)

Region (BRL Mn)FY2023FY2024FY2025

Brazil revenue

2,875.93,304.33,697.3

Rest of world revenue

000

Brazil revenue growth (%)

23.514.911.9

Share Price and Margin Analysis (%)

MetricOct2021Oct2022Oct2023Oct2024Oct2025Oct2026

AFYA share price (USD)

17.4514.7416.1016.7614.1713.92

Return, price only (computed)

1 year

3 years

5 years

———

AFYA price change (%)

-1.8-13.5-20.2———

Valuation Multiples

MultipleAfya (LTM 2Q26)

P/E (x)

8.0

EV/EBITDA, ex-leases (x)

4.6

EV/Sales (x)

2.0

P/B (x)

1.3

Capital Markets

ItemDetail

Dividend policy

No fixed policy disclosed. Payout of 20% of FY2024 net income, raised to 40% of FY2025 net income.

FY2024 dividend

Declared Mar 2025: 20% of FY2024 net income (about R$130M, computed)

FY2025 dividend

R$307.4M (R$3.446838 per share), declared 12 Mar 2026, paid 6 Apr 2026 in US dollars

Buybacks

Three programmes completed in 2022 (R$152.3M); R$12.4M in 2023; R$77.0M in 2025; R$133.0M (2.7M shares) in 1H26 under the 4.0M-share programme running to 31 Dec 2026

Merger constraints

From 30 Jun 2026, Afya may distribute only its adjusted FCFE plus any top-up. Treasury-share changes outside permitted distributions count as "leakage".

Credit Ratings

AgencyRatingOutlookDate

Moody's (national scale)

AAA.br

Stable

Reaffirmed 5 May 2026

Capital Instruments

InstrumentAmountCostMaturity / duration

Commercial notes / debentures

1,538

15.2% per year (106% of CDI)

R$500M due Oct 2028 (CDI + 0.70%); R$1,000M due Oct 2030 (CDI + 0.85%); duration 3.9 years

IFC loan

510

15.5% per year (108% of CDI)

Duration 2.8 years

Accounts payable to selling shareholders

353

14.3% per year (100% of CDI)

Duration 4.4 years

Total

2,400

15.1% per year (106% of CDI)

Average duration 3.7 years

Analyst Conclusions

Management guidance for FY2026

ItemFY2026 rangeImplied change at midpoint vs FY2025
RevenueR$3,950–4,100M+8.9%
Adjusted EBITDAR$1,700–1,800M+4.1%
Adjusted EBITDA marginAbout 43.5% at midpoint-190 bps
CapexR$340–380M—

Guidance was reaffirmed on 13 August 2026.

The 1H26 run-rate (revenue +7.0%, adjusted EBITDA +2.8%) points to the lower half of the revenue range.

Bull case

  1. Merger re-rating and synergies. The combined group would trade on B3, with possible index inclusion and deeper local liquidity. Synergy NPV of R$2.0–2.2bn is equivalent to about 21% upside for Afya holders if fully realised (Itaú BBA). Pro-forma leverage would fall to 1.2x.

  2. Cash yield. LTM FCFE yield is about 11%, EPS growth was 18.7% in FY2025, and payout was 106% of 1H26 FCFE. On management's framing that implies about 24% potential annual equity return.

  3. Scarcity value. Seats change hands at about R$1.8M each in M&A. Afya's 3,768 seats alone would exceed its enterprise value at those prices, which suggests the market is pricing in material ENAMED or regulatory discounting.

Bear case

  1. Unfavourable deal terms. The exchange ratio favours YDUQS holders by about 6% (JPMorgan, Itaú BBA). YDUQS's R$750M pre-closing dividend is equivalent to about a 38% yield on YDUQS's own market value. US retail holders face a forced cash-out at B3 prices.

  2. ENAMED escalation. Several courses already face sanctions. A poor October 2026 ENAMED result could turn temporary measures into permanent seat losses, directly eroding the core profit pool.

  3. Ecosystem thesis fading. MPS monthly active users are falling, Residency Journey students fell 20.7%, and 2026 margins are compressing through investment with no disclosed payback metrics.

Key catalysts and monitorables (next 12 months)

  1. Content of Afya Day 2026 (20 Oct 2026): any update on synergies or targets.

  2. 3Q26 results (expected November 2026): delivery against FY2026 guidance and the second-semester medical intake.

  3. ENAMED 2026 results and any MEC revision of the 2025 sanctions.

  4. CADE filing, review timeline (up to about 330 days) and possible divestitures in Ji-Paraná, Rio de Janeiro and Teresina.

  5. Dates and vote outcomes for the Afya and YDUQS extraordinary general meetings, including dissenter levels under Section 238.

  6. YDUQS's use of its R$750M distribution allowance and any Afya top-up.

  7. Pillar Two tax normalisation and the effective tax rate.

  8. Final buyback execution under the 4.0M-share programme before 31 Dec 2026.

  9. The FY2026 dividend decision (March 2027) within the merger's leakage rules.

  10. Nasdaq delisting and SEC deregistration mechanics.

Analyst verdict

Afya enters late 2026 as a fundamentally sound but strategically repositioning asset.

The standalone franchise remains one of the highest-quality education businesses in emerging markets:

  • the largest licensed medical-seat base in a supply-rationed market;

  • adjusted EBITDA margins in the mid-40s;

  • cash conversion above 90%;

  • leverage below 1x;

  • seven straight years of meeting guidance.

These qualities justified a premium to Brazilian education peers for most of its listed life.

Three developments have changed the debate.

First, growth has decelerated to mid-single digits, and management has chosen to reinvest margin into a physician ecosystem whose engagement metrics are not yet improving. Second, ENAMED has turned quality into a direct regulatory variable for seat counts, undermining the assumption that scarcity is permanent. Third, and most decisive, the YDUQS merger converts AFYA from a pure medical-education play into the controlling 69% of a diversified B3-listed group, with medicine at about 45% of revenue, broader non-medical exposure and a higher-tax counterparty.

On the evidence, the exchange ratio is modestly favourable to YDUQS. That cost is likely outweighed if the R$2.0–2.2bn synergy NPV is captured and B3 listing improves liquidity and index eligibility. The deal also crystallises a valuation floor near the agreed ratio, and the shares' recovery from about US$11.8 to about US$13.9 after the JPMorgan upgrade suggests the market is beginning to price this.

The principal residual risks are regulatory: CADE remedies in three overlapping cities, and ENAMED 2026 outcomes on the courses already sanctioned. Execution of a large, cross-border, dual-regime merger also carries tax and dissenter complexity.

On balance, at about 4.6x LTM EV/EBITDA (ex-leases) and about 8x earnings, the shares discount a large share of the regulatory risk while offering roughly an 11% cash yield. The investment case is now best framed as event-driven, with a quality underlying business. Holders should prioritise the ENAMED and CADE milestones over standalone growth metrics through 2027.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenure / backgroundCompensation

Virgilio Deloy Capobianco Gibbon

Chief Executive Officer

CEO at least since the July 2019 IPO. Designated CEO of the combined Afya–YDUQS company.

Not individually disclosed (see note)

Luis André Carpintero Blanco

Chief Financial Officer

CFO since May 2020. Previously CFO of OdontoPrev for about 10 years, and earlier CFO of Tele Centro-Oeste Celular (2000–03).

Not individually disclosed

Renata Costa Couto

Investor Relations Director

Long-tenured IR lead; was IR contact at the 2019 IPO

—

“—” = not publicly disclosed.

Board of Directors

NameRoleAffiliationNotes

Kay Krafft

Co-Chairman (since May 2022; director since Aug 2021)

Bertelsmann

Founding CEO of Bertelsmann Education Group; former Deloitte partner. Designated Chairman of the combined company.

Nicolau Carvalho Esteves

Co-Chairman (since May 2022; Chairman Jul 2019–May 2022)

Esteves family (founder)

Orthopaedic surgeon with more than 25 years in education; chaired Afya Brazil from Aug 2016

Renato Tavares Esteves

Director (since Jul 2019)

Esteves family

Son of Nicolau Esteves

Two further Bertelsmann nominees

Directors

Bertelsmann

Names not confirmed in 2026 sources.

Vanessa Claro Lopes

Independent director; audit committee (since Jul 2019)

Independent

Re-appointed at the 2025 AGM for a two-year term

Miguel Filisbino Pereira de Paula

Independent director

Independent

Re-appointed at the 2025 AGM

Marcelo Ken Suhara

Independent director; Audit, Risks & Ethics Committee Chair (since 27 Jul 2026); audit committee financial expert

Independent

Succeeded the late João Paulo Seibel de Faria

João Paulo Seibel de Faria

Former independent director and Audit Chair (2020–2026)

—

Died in July 2026

Major Shareholders

HolderStakeSource / caveat

Bertelsmann (Erste WV Gütersloh GmbH)

About 31% of total shares and about 57.5% of votes after May 2022 (Class B shares carry 10 votes each)

Afya release, 4 May 2022. Press reports say Bertelsmann would hold 47.3% of the combined company after the merger, which implies a materially larger current economic interest than 31%. Unreconciled; verify in the merger documents.

Esteves family (Nicolau Carvalho Esteves, NRE Capital Ventures Ltd)

About 18% of total shares and about 33% of votes after May 2022

Same source. Party to the 2026 voting agreement.

Institutional investors (Class A free float)

Aggregators report about 88% of the free float held by institutions

MarketBeat (aggregator).

Insiders, excluding the controlling bloc

About 0.8%

Aggregator

SoftBank (SBLA Holdco)

Exited; preferred shares repurchased 3 Nov 2025

FY2025 6-K

Competitive Landscape

Competitors by Segment

SegmentCompetitorPositioning vs AfyaComparative data

Medical undergraduate

YDUQS (IDOMED / Estácio / Ibmec)

Number 2 in private medical seats; merger counterparty

2,120 medical seats across 19 schools; about 5.5–6% of private seats. LTM revenue about R$5.6bn (computed: combined R$9.4bn minus Afya's R$3.8bn).

Medical undergraduate

Ânima Educação (Inspirali medical vertical)

Large listed medical-education player

—

Medical undergraduate

Cogna Educação (Kroton)

Largest Brazilian education group; smaller medical exposure

—

Medical undergraduate

Ser Educacional

North/Northeast regional competitor with medical schools

—

Medical undergraduate

Cruzeiro do Sul Educacional

Diversified group with medical schools

—

Medical undergraduate

Grupo Tiradentes (UNIT, Sergipe)

Northeast medical schools; sold the DelRey assets to Afya

—

Medical undergraduate

Federal and state public universities

Free tuition, highly selective; shapes national seat supply

—

Residency preparation (Continuing Education)

Medway, MedGrupo (Medcurso), Estratégia MED, Sanar, Aristo

Digital-first prep players; Afya cited intensified competition affecting Medcel from 2022

Private; financials not disclosed

Medical post-graduate

Hospital-linked schools and specialty societies

Fragmented market

—

Clinical decision support

UpToDate (Wolters Kluwer), Medscape, local apps

Whitebook leads in Portuguese-language mobile reference

—

Practice management / EMR

Doctoralia (Docplanner), Feegow, Amplimed, Conexa Saúde

Competing SaaS and telehealth offerings

—

Digital prescription

Memed and others

Overlaps with iClinic features

—

“—” = not publicly disclosed.

Peer Comparison FY2025

MetricAfya FY2025YDUQS (LTM Jun-2026, approx.)Combined (LTM Jun-2026)

Revenue (BRL Bn)

3.705.69.4

Adjusted EBITDA (BRL Bn)

1.681.93.6

Adjusted EBITDA margin (%)

45.43438

Medical seats

3,7682,1205,888

Recent Developments

Guidance was reaffirmed twice.

Company Snapshot

$660.2M

Revenue

9,395

Employees

$1,230M

Market Cap

1999

Founded

Belo Horizonte, Brazil

Headquarters

SWOT Analysis

Strengths

  • Scale leadership. 3,768 operating medical seats, the largest private medical-school network in Brazil, at about 10–11% of private seats (2Q26 6-K; analyst estimates).
  • Pricing power. The medical-school net ticket rose 3.9% to R$9,443 per month in 1H26, after a 2.8% rise to R$9,060 in FY2025.
  • Margins. FY2025 adjusted EBITDA margin was 45.4% and gross margin 64.5%, well above diversified Brazilian education peers (YDUQS is about 34% on a derived basis).
  • Cash conversion. Operating cash conversion was 93.7% in FY2025 and 102.2% in FY2024. Simple free cash flow was about R$1.17bn in FY2025.
  • Balance sheet. Net debt ex-IFRS 16 was 0.8x adjusted EBITDA in FY2025, with Moody's AAA.br stable (May 2026) and a covenant ceiling of 3.0x.
  • Execution record. Afya has met or exceeded guidance for seven consecutive years since 2H19 (FY2025 6-K).
  • Diversified footprint. The top five cities account for only 29.8% of seats (Itaú BBA).

Weaknesses

  • Slowing growth. Revenue growth fell from 14.9% in FY2024 to 11.9% in FY2025 and 5.7% in 2Q26. Medical students grew only 2.7% year on year in 1H26.
  • Digital underperformance. MPS revenue grew just 1.5% in 1H26. Monthly active users fell 7.9%, and Clinical Decision payers fell 5.9%.
  • Residency-prep erosion. Residency Journey students fell 20.7% in FY2025, and Continuing Education B2B revenue fell 25.4% in 1H26.
  • Margin compression. The 2Q26 adjusted EBITDA margin was 41.8%, down 180 bps. FY2026 guidance implies about 190 bps of full-year dilution.
  • Rising cost of debt. The average cost was 15.1% per year in 1H26, up from 12.7%, after the cheap SoftBank financing was retired.
  • Thin liquidity. AFYA traded about R$5M per day on Nasdaq, roughly 0.5% of float (Brazil Journal). Aggregator sentiment is weak: one buy, seven holds and five sells.

Opportunities

  • YDUQS merger synergies. NPV of R$2.0–2.2bn, about 80% within three years, with pro-forma leverage falling to 1.2x (companies; JPMorgan).
  • B3-only listing. Index inclusion could lift liquidity towards about R$100M per day (Brazil Journal).
  • Broader M&A universe. As part of a diversified group, Afya could pursue non-medical assets it previously passed over (Brazil Journal).
  • Health-sciences growth. Students rose 18% in 1H26, and the segment could be cross-sold into the physician ecosystem.
  • Graduate Journey expansion. Students rose 20% in FY2025, providing post-graduate monetisation.
  • Clinical Management SaaS. Active payers rose 20.4% in 1H26, offering a platform for B2B data and pharma revenue.

Threats

  • ENAMED sanctions. About 30% of graded courses scored poorly nationally, and several Afya courses face seat cuts or FIES suspension. The October 2026 results could extend or worsen the measures.
  • CADE remedies. Combined shares exceed 45% in Ji-Paraná, Rio de Janeiro and Teresina, which together represent about 15% of combined seats. Review could take up to 330 days.
  • Unfavourable exchange ratio. Analysts estimate the ratio favours YDUQS holders by about 6%. US non-institutional holders will be cashed out rather than receive shares.
  • Tax. Pillar Two raised FY2025 tax to R$92.5M. Analysts flag higher income-tax exposure at YDUQS.
  • Rates. CDI around 14.7–14.9% inflates finance costs, with a net finance result of R$366M in FY2025.
  • Policy risk. Mais Médicos and FIES rules can change with federal administrations.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
May 2025FUNIC acquisition closes (60 seats; R$99.6M licence)Seat growth; one-off capex
Jun 2025AGM re-appoints independent directors (Seibel de Faria, Claro Lopes, Pereira de Paula)Governance continuity
Aug 2025Board approves buyback of up to 4.0M Class A shares through 31 Dec 2026Capital return
13 Aug 20252Q25 results: adjusted EBITDA +16.6%, margin 43.6%; guidance reaffirmedPeak-margin period
15 Oct 2025R$1.5bn commercial notes issued (CDI + 0.70% / + 0.85%; maturities 2028 and 2030)Refinancing; covenant of net debt/EBITDA ≤ 3.0x
3 Nov 2025SoftBank preferred shares repurchased and cancelled (R$18M gain)SoftBank exit; simplified structure
7 Nov 2025MEC authorises +100 seats at Bragança (PA)Seat growth
Nov 2025Strong momentum
17 Dec 2025Maria Tereza Azevedo announces resignation effective 31 Dec 2025Board change; female representation falls
18 Dec 2025MEC authorises +2 seats at Pato Branco (PR)Approved seats reach 3,755
19 Jan 2026MEC publishes ENAMED 2025 results; about 30% of graded courses insufficientRegulatory shock to the sector
Q1 2026MEC authorises +63 seats at Abaetetuba; Cametá relinquishedApproved and operating seats reach 3,768
12 Mar 2026FY2025 results (revenue R$3,697M, adjusted EBITDA R$1,680M); 2026 guidance; R$307.4M dividendGuidance implies margin compression
17 Mar 2026MEC ordinances sanction or supervise several Afya medical coursesSeat-count and FIES risk
6 Apr 2026FY2025 dividend paid (R$3.446838 per share)Shareholder return
5 May 2026Moody's reaffirms AAA.br, stable outlookCredit strength
7 May 20261Q26 results: revenue +8.2% to R$1,012.7M; adjusted EBITDA +4.0%Slowing growth
22 Jun 2026AGM approves FY2025 accountsRoutine
Jul 2026Death of independent director and Audit Chair João Paulo Seibel de FariaGovernance gap
27–29 Jul 2026Marcelo Ken Suhara named Audit, Risks & Ethics Committee ChairAudit continuity
13 Aug 20262Q26 results: revenue +5.7%, adjusted EBITDA +1.4%, margin 41.8%, net income +14.0%; R$447.9M returned in 1H26; guidance reaffirmedMargin pressure; high payout
About 24 Aug 2026Afya and YDUQS confirm preliminary merger talks; YDUQ3 shares jump about 12.6%Strategic pivot
8 Sep 2026Bradesco BBI publishes merger fair-value framework (AFYA US$14.30; YDUQ3 R$14.40)Valuation anchor
23 Sep 2026Binding merger agreement and voting agreement signedTransformational
24 Sep 2026JPMorgan and Itaú BBA say the exchange ratio favours YDUQS by about 6%Afya holders perceive dilution
29 Sep 2026AFYA closes at about US$11.82 (post-announcement low)Market scepticism
30 Sep – 1 Oct 2026Merger agreement and voting agreement filed publicly (6-K)Deal terms disclosed
1 Oct 2026Afya Day 2026 announced for 20 October in Rio de JaneiroStrategy update
7 Oct 2026JPMorgan upgrades AFYA to Overweight from Neutral; stock up about 17.7% in a week to US$13.92Re-rating
Oct 2026ENAMED 2026 exam edition scheduled; results will determine whether 2025 sanctions are revoked, extended or worsenedKey regulatory catalyst
20 Oct 2026Afya Day 2026 (research cut-off date; outcomes not captured)Monitor

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

7 charts
Income Statement: Revenue & Gross Profit: Revenue rose from BRL 1,719.4 Mn in FY2021 to BRL 3,697.3 Mn in FY2025.
Afya Limited — Income Statement: Revenue & Gross Profit
Series (BRL Mn)FY2021FY2022FY2023FY2024FY2025
Revenue1,719.42,329.12,875.93,304.33,697.3
Adjusted net revenue (FY21–23 non-GAAP)1,752.72,319.12,874.13,304.33,697.3
Cost of services——1,109.81,215.61,313.9
Gross profit——1,766.12,088.72,383.4

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Afya 6-K Ex-99.1: 4Q22/FY2022 (22 Mar 2023); 4Q23/FY2023 (14 Mar 2024); 4Q24/FY2024 (13 Mar 2025); 2Q25 (13 Aug 2025); 3Q25 (Nov 2025); 4Q25/FY2025 (12 Mar 2026); 1Q26 (7 May 2026); 2Q26 (13 Aug 2026). Sources: sec.gov, businesswire.com, ir.afya.com.br.
  2. Merger Agreement and Other Covenants, Afya Limited and YDUQS Participações S.A., dated 23 Sep 2026 (Business Wire / 6-K, 30 Sep – 1 Oct 2026): Voting Commitment Agreement (same date).
  3. Afya releases: Bertelsmann stake transactions (5 Aug 2021; 7 Mar, 22 Apr, 4 May 2022); board changes (20 Apr 2022; 9 Dec 2022; 1 Jul 2024; 17 Dec 2025; 29 Jul 2026); dividend (12 Mar 2026) · AGM results (2025, 2026) · Afya Day 2026 notice.
  4. IPO references: Renaissance Capital (18 Jul 2019) · Cleary Gottlieb (22 Jul 2019) · IPO listing release. Afya IR history page.
  5. Press and analyst coverage (secondary): Brazil Journal · Bloomberg Línea (24 Sep 2026) · Money Times / JPMorgan (23 Sep 2026) · Itaú BBA via EuQueroInvestir · Bradesco BBI / Ágora (25 Aug 2026; 8 Sep 2026) · TradeMap · Poder360 · Times Brasil / CNBC · InvestNews · Valor International (via ad-hoc-news) · StreetInsider · Rio Times.
  6. ENAMED coverage: MEC via Metrópoles, Jovem Pan, Carta Capital, Bem Paraná, Diario de Pernambuco, O Imparcial, Correio Braziliense (Jan–Mar 2026).
  7. Market data (aggregators, flagged): Robinhood, Stockanalysis, Digrin price history, Fintel/Nasdaq (JPMorgan upgrade, 7 Oct 2026), MarketBeat, roic.ai, Quiver Quant.

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.